阿托伐他汀联合普罗布考对急性心肌梗死患者血脂和高敏C反应蛋白的影响

【目的】评价阿托伐他汀联合普罗布考对急性心肌梗死（AMI）患者血脂和高敏c反应蛋白（hs～CRP）的影响。【方法】将53例AMI患者随机分为单独治疗组（n=27，阿托伐他汀20mg／d）和联合治疗组（n=26，普罗布考0．5g／d，阿托伐他汀20mg／d）。疗程均为4周。分别测量两组患者服药前和服药1个月后的外周血血脂和hs-CRP等指标变化。【结果】①血脂变化：经治疗4周后，两组总胆固醇（TC）水平均显著下降，其中联合治疗组TC水平下降更明显，两组间比较差异有显著性（P〈0．05）。两组甘油三酯（TG），低密度脂蛋白胆固醇（LDL-C）水平在治疗4周后均显著下降，两组间无统计学差异。联合治疗组高密度脂蛋白胆固醇（HDL-C）水平显著下降（P〈0．01）；而单独治疗组HDL-C水平无明显变化。②两组患者治疗后血清hs-cRP水平较治疗前均明显降低（P〈0．01），但联合治疗组降低的幅度较单独治疗组大（P〈0．05）。【结论】普罗布考联合阿托伐他汀与单用阿托伐他汀均可明显降低AMI患者近期TC、TG及LDL-C水平．联合治疗组同时降低HDL-C水平；联合治疗可显著降低血清hs-cRP水平抑制炎症反应。

Effect of Atorvastatin Combined with Probucol on Blood Lipids and hs-CRP Level in Patients with Early Stage of Acute Myocardial Infarction

[Objective]To investigate the effect of atorvastatin combined with probucol on blood lipids and high-sensitivity C-reactive protein （ hs-CRP ） levels after 1 month of treatment. [Methods] Fifty-three patients with acute myocardial infarction （AMI） were assigned to atorvastatin group（ 20 mg/d of atorvastatin, n=27 ） and combined treatment group （20 mg /d of atorvastatin and 0.5g/d of probucol, n=26） at random. Blood lipids and hs-CRP were detected before and after treatment. [Results]（1） The changes of blood lipids： ①After treatment, serum level of triglyceride （TG） was reduced in both groups, but it was significant in com- bined treatment group （P〈0.05） .②After treatment, serum level of low density lipoprotein cholesterol （LDL-C） was just slightly reduced in both groups （P〉0.05）.③in combined treatment group, serum level of TG and high density lipoprotein cholesterol （HDL-C） were significantly decreased （P〈0.01）. （2）After treatment, the level of serum hs-CRP was significantly decreased （p〈0.01）, which in combined treatment group decreased even more markedly （P〉0.05） . [Conclusion] Combination therapy of probucol and atorv-astatin has stronger linid-lowering and anti-inflammatory effects than those of monotherapy.